Article Text
Letter
Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis
Statistics from Altmetric.com
Raynaud’s phenomenon (RP) with or without digital ulcer formation is a significant cause of morbidity for patients with systemic sclerosis (SSc, scleroderma). Lichtenstein reported oral sildenafil as a treatment of RP for patients with SSc, systemic lupus erythematosus, and idiopathic RP.1 His report included 10 patients from his community office practice given sildenafil, 50 mg once orally at bedtime.
METHODS AND RESULTS
We performed a retrospective chart review of 10 patients with SSc seen at a tertiary care referral centre who were offered sildenafil after standard treatments (calcium channel …